2016 Baptist Health Research Summit Evaluation - November 5, 2016

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Explain elements of creating a new system for cancer research and management.	Explain elements of creating a new system for cancer research and management. - 5	Explain elements of creating a new system for cancer research and management. - 4	Explain elements of creating a new system for cancer research and management. - 3	Explain elements of creating a new system for cancer research and management. - 2	Explain elements of creating a new system for cancer research and management. - 1	Explain elements of creating a new system for cancer research and management. - 0
Integrate key factors in the value proposition into the implementation of cancer care programs.	Integrate key factors in the value proposition into the implementation of cancer care programs. - 5	Integrate key factors in the value proposition into the implementation of cancer care programs. - 4	Integrate key factors in the value proposition into the implementation of cancer care programs. - 3	Integrate key factors in the value proposition into the implementation of cancer care programs. - 2	Integrate key factors in the value proposition into the implementation of cancer care programs. - 1	Integrate key factors in the value proposition into the implementation of cancer care programs. - 0
Describe how clinical pathways are integral to the creation of a symmetrical health care system.	Describe how clinical pathways are integral to the creation of a symmetrical health care system. - 5	Describe how clinical pathways are integral to the creation of a symmetrical health care system. - 4	Describe how clinical pathways are integral to the creation of a symmetrical health care system. - 3	Describe how clinical pathways are integral to the creation of a symmetrical health care system. - 2	Describe how clinical pathways are integral to the creation of a symmetrical health care system. - 1	Describe how clinical pathways are integral to the creation of a symmetrical health care system. - 0
Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy.	Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy. - 5	Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy. - 4	Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy. - 3	Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy. - 2	Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy. - 1	Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy. - 0
Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies.	Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies. - 5	Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies. - 4	Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies. - 3	Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies. - 2	Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies. - 1	Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies. - 0
Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios.	Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios. - 5	Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios. - 4	Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios. - 3	Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios. - 2	Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios. - 1	Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios. - 0
Differentiate the approximate proportion of all cancers that are associated with inherited predisposition.	Differentiate the approximate proportion of all cancers that are associated with inherited predisposition. - 5	Differentiate the approximate proportion of all cancers that are associated with inherited predisposition. - 4	Differentiate the approximate proportion of all cancers that are associated with inherited predisposition. - 3	Differentiate the approximate proportion of all cancers that are associated with inherited predisposition. - 2	Differentiate the approximate proportion of all cancers that are associated with inherited predisposition. - 1	Differentiate the approximate proportion of all cancers that are associated with inherited predisposition. - 0
Recognize certain more common hereditary cancer syndromes.	Recognize certain more common hereditary cancer syndromes. - 5	Recognize certain more common hereditary cancer syndromes. - 4	Recognize certain more common hereditary cancer syndromes. - 3	Recognize certain more common hereditary cancer syndromes. - 2	Recognize certain more common hereditary cancer syndromes. - 1	Recognize certain more common hereditary cancer syndromes. - 0
Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals.	Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals. - 5	Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals. - 4	Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals. - 3	Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals. - 2	Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals. - 1	Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals. - 0
Outline various strategies for reducing the risk of genetic predisposition for some cancers.	Outline various strategies for reducing the risk of genetic predisposition for some cancers. - 5	Outline various strategies for reducing the risk of genetic predisposition for some cancers. - 4	Outline various strategies for reducing the risk of genetic predisposition for some cancers. - 3	Outline various strategies for reducing the risk of genetic predisposition for some cancers. - 2	Outline various strategies for reducing the risk of genetic predisposition for some cancers. - 1	Outline various strategies for reducing the risk of genetic predisposition for some cancers. - 0
Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today.	Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today. - 5	Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today. - 4	Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today. - 3	Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today. - 2	Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today. - 1	Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today. - 0
Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on.	Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on. - 5	Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on. - 4	Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on. - 3	Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on. - 2	Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on. - 1	Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on. - 0
Appraise the current status of immunotherapy and the promise of this field for the future.	Appraise the current status of immunotherapy and the promise of this field for the future. - 5	Appraise the current status of immunotherapy and the promise of this field for the future. - 4	Appraise the current status of immunotherapy and the promise of this field for the future. - 3	Appraise the current status of immunotherapy and the promise of this field for the future. - 2	Appraise the current status of immunotherapy and the promise of this field for the future. - 1	Appraise the current status of immunotherapy and the promise of this field for the future. - 0
Describe the unique role of the research nurses in clinical trial delivery.	Describe the unique role of the research nurses in clinical trial delivery. - 5	Describe the unique role of the research nurses in clinical trial delivery. - 4	Describe the unique role of the research nurses in clinical trial delivery. - 3	Describe the unique role of the research nurses in clinical trial delivery. - 2	Describe the unique role of the research nurses in clinical trial delivery. - 1	Describe the unique role of the research nurses in clinical trial delivery. - 0
Discuss methods for integrating research nurses into the multidisciplinary research team.	Discuss methods for integrating research nurses into the multidisciplinary research team. - 5	Discuss methods for integrating research nurses into the multidisciplinary research team. - 4	Discuss methods for integrating research nurses into the multidisciplinary research team. - 3	Discuss methods for integrating research nurses into the multidisciplinary research team. - 2	Discuss methods for integrating research nurses into the multidisciplinary research team. - 1	Discuss methods for integrating research nurses into the multidisciplinary research team. - 0
Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials.	Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials. - 5	Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials. - 4	Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials. - 3	Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials. - 2	Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials. - 1	Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials. - 0

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.

	5	4	3	2	1
Derek Raghavan, MD PhD FACP FRACP FASCO - Keynote: The Challenge of a Clean Slate	Derek Raghavan, MD PhD FACP FRACP FASCO - Keynote: The Challenge of a Clean Slate - 5	Derek Raghavan, MD PhD FACP FRACP FASCO - Keynote: The Challenge of a Clean Slate - 4	Derek Raghavan, MD PhD FACP FRACP FASCO - Keynote: The Challenge of a Clean Slate - 3	Derek Raghavan, MD PhD FACP FRACP FASCO - Keynote: The Challenge of a Clean Slate - 2	Derek Raghavan, MD PhD FACP FRACP FASCO - Keynote: The Challenge of a Clean Slate - 1
Miguel Villalona-Calero, M.D. - Molecular Targeted Therapy and Immunotherapy	Miguel Villalona-Calero, M.D. - Molecular Targeted Therapy and Immunotherapy - 5	Miguel Villalona-Calero, M.D. - Molecular Targeted Therapy and Immunotherapy - 4	Miguel Villalona-Calero, M.D. - Molecular Targeted Therapy and Immunotherapy - 3	Miguel Villalona-Calero, M.D. - Molecular Targeted Therapy and Immunotherapy - 2	Miguel Villalona-Calero, M.D. - Molecular Targeted Therapy and Immunotherapy - 1
Jeffrey Boyd, Ph.D. - Genetic Predisposition in Cancer	Jeffrey Boyd, Ph.D. - Genetic Predisposition in Cancer - 5	Jeffrey Boyd, Ph.D. - Genetic Predisposition in Cancer - 4	Jeffrey Boyd, Ph.D. - Genetic Predisposition in Cancer - 3	Jeffrey Boyd, Ph.D. - Genetic Predisposition in Cancer - 2	Jeffrey Boyd, Ph.D. - Genetic Predisposition in Cancer - 1
Minesh Mehta, MD, FASTRO - Innovations in Radiation Oncology	Minesh Mehta, MD, FASTRO - Innovations in Radiation Oncology - 5	Minesh Mehta, MD, FASTRO - Innovations in Radiation Oncology - 4	Minesh Mehta, MD, FASTRO - Innovations in Radiation Oncology - 3	Minesh Mehta, MD, FASTRO - Innovations in Radiation Oncology - 2	Minesh Mehta, MD, FASTRO - Innovations in Radiation Oncology - 1
Dorothy Dulko, Ph.D., RN, NP-C - The Role of Research Nursing in the Multidisciplinary Delivery of Quality Clinical Trials	Dorothy Dulko, Ph.D., RN, NP-C - The Role of Research Nursing in the Multidisciplinary Delivery of Quality Clinical Trials - 5	Dorothy Dulko, Ph.D., RN, NP-C - The Role of Research Nursing in the Multidisciplinary Delivery of Quality Clinical Trials - 4	Dorothy Dulko, Ph.D., RN, NP-C - The Role of Research Nursing in the Multidisciplinary Delivery of Quality Clinical Trials - 3	Dorothy Dulko, Ph.D., RN, NP-C - The Role of Research Nursing in the Multidisciplinary Delivery of Quality Clinical Trials - 2	Dorothy Dulko, Ph.D., RN, NP-C - The Role of Research Nursing in the Multidisciplinary Delivery of Quality Clinical Trials - 1

Was this course fair, balanced and without commercial bias? *

Yes

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

If you checked "No,” please tell us why: *

If you checked "No,” please explain why you would not recommend this course: *

What do you intend to do differently in the treatment of your patients as a result of what you learned? What new strategies will you apply in your practice of patient care? *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

Leave this field blank

You are here

2016 Baptist Health Research Summit Evaluation - November 5, 2016